Shariftabrizi, Ahmad MD∗; Pillenahalli Maheshwarappa, Ravishankar MD, MBBS†; Kahn, Daniel MD∗; Pollard, Janet MD‡
Author Information
From the ∗Iowa City Veterans Affairs Health Care System
†University of Iowa Hospitals and Clinics
‡Department of Nuclear Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA.
Received for publication May 18, 2020; revision accepted August 23, 2020.
This is an off-label use of 18F-fluciclovine in a newly diagnosed prostate cancer. This radiotracer is US Food and Drug Administration approved for use in cases of biochemical recurrence of prostate cancer to detect any evidence of recurrent prostate cancer on imaging.
Conflicts of interest and sources of funding: none declared.
Correspondence to: Ahmad Shariftabrizi, MD, Division of Molecular Imaging and Therapy, University of Iowa Carver College of Medicine, and Iowa City Veterans Affairs Medical Center, Room 2W30, 601 Highway 6 West (05), Iowa City, IA 52246. E-mails: [email protected], [email protected].
doi: 10.1097/RLU.0000000000003319
